Gastroesophageal Reflux Disease (GERD) Segmentation
Drug Type (Antacids, Proton Pump Inhibitors, H2 Receptor Blocker, Pro Kinetic Agents, Dopamine Receptor Antagonist, EndoCinch, Stretta, EsophyX, Transoral Incisionless, Fundoplication)
The antacids segment value is poised to be the greatest among the others in the gastroesophageal reflux disease market with a share of 26% by 2037. This is due to the fast and effective relief that antacids provide. Antacids are also useful in various related symptoms, including heartburn, acid indigestion, hyperacidity, upset stomach, and others. Furthermore, the widespread awareness about self-medication has led to the higher consumption of antacids rather than visiting healthcare systems. In addition to other benefits, antacids have minimal to no side effects and are even safe for pregnant women. All these factors accumulatively create a positive outlook for segment expansion in the upcoming years.
Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
The hospital pharmacy sub-segment is set to register a significant growth rate in the gastroesophageal reflux disease market over the assessed period. The major factor projected to support in the propagation of this segment is the rising number of in-house pharmacies in hospitals which increases the access to medications for the patients’ visiting. In this regard, an NLM article from November 2022, reported that the proportion of pharmaceutical expenditure in hospitals ranged between 20.0% and 50.0% of the total third-party drug spending in Europe. In addition, the favorable reimbursement policies available in these organizations are estimated solidify its propagation.
Our in-depth analysis of the global gastroesophageal reflux disease market includes the following segments:
|
Drug Type |
|
|
Route of Administration |
|
|
Distribution Channel |
|
|
End user |
|
